<DOC>
	<DOCNO>NCT01712178</DOCNO>
	<brief_summary>A study Rheumatoid Arthritis ( RA ) patient evaluate two formulation adalimumab pharmacodynamics , pharmacokinetics , safety .</brief_summary>
	<brief_title>A Study Rheumatoid Arthritis ( RA ) Patients Compare Two Formulations Adalimumab Pharmacokinetic , Pharmacodynamic Safety</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male female subject , 18 year old diagnosis Rheumatoid Arthritis ( RA ) define 1987revised American College Rheumatology ( ACR ) classification criterion new American College Rheumatology ( ACR ) /European League Against Rheumatism ( EULAR ) diagnostic criterion RA 2010classification criterion disease duration minimum 3 month . Subjects must naïve biologic therapy . Subject must meet follow criterion joint assessment : • At least 6 swollen joint 66 assess . • At least 6 tender joint 68 assess . Prior Disease Modifying Antirheumatic Drug ( DMARD ) therapy : ) Subjects methotrexate baseline must remain without methotrexate throughout study . Subjects prior Methotrexate ( MTX ) must discontinue least 28 day prior Week 0 ( Day 1 ) . b ) Subjects Disease Modifying Antirheumatic Drug ( DMARD ) therapy Methotrexate ( MTX ) ( except prednisone/prednisolone le equal 10 mg ) must discontinue least 28 day first dose investigational product Week 0 ( Day 1 ) . Female subject either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy and/or hysterectomy ) , practice least 1 follow method birth control throughout study least 150 day last dose study drug : • Condoms , sponge , foam , jelly , diaphragm intrauterine device ( IUD ) . • Hormonal contraceptive 90 day prior study drug administration . • Vasectomized partner ( ) . Subjects must able willing selfadminister subcutaneous ( SC ) injection qualify person available administer subcutaneous ( SC ) injection . Subject judge good general health determine Principal Investigator base upon result medical history , physical examination , laboratory profile , chest xray ( CXR ) , 12 lead electrocardiogram ( ECG ) perform Screening . Subject negative Tuberculosis ( TB ) screen assessment ( include ( Purified Protein Derivative ( PPD ) test QuantiFERONTuberculosis ( TB ) Gold test equivalent ) negative chest xray ( PosteriorAnterior ( PA ) lateral view ) Screening . If subject evidence latent Tuberculosis ( TB ) infection , subject must initiate complete minimum 2 week antiTuberculosis ( TB ) therapy document completion course antiTuberculosis ( TB ) therapy prior Baseline . Subjects must willing provide write consent comply requirement study protocol . Subject treat intraarticular parenteral administration corticosteroid precede 4 week Baseline visit . Inhaled corticosteroid stable medical condition allow . Oral le equal 10 mg/d prednisone equivalent allow . Subject treated investigational drug chemical biological nature within minimum 30 day 5 halflives ( whichever longer ) drug prior Baseline Visit . Subject history acute inflammatory joint disease different origin Rheumatoid Arthritis ( RA ) ( e.g. , seronegative spondyloarthropathy , psoriatic arthritis , Reiter 's syndrome , systemic lupus erythematosus , gouty arthritis , arthritis onset prior age 17 year ) . Known hypersensitivity adalimumab excipients . Subject currently use plan use antiretroviral therapy time study . History demyelinate disease ( include myelitis ) neurologic symptom suggestive demyelinate disease . History invasive infection ( e.g. , listeriosis histoplasmosis ) , human immunodeficiency syndrome ( HIV ) . Chronic recur infection active Tuberculosis ( TB ) . History moderate severe congestive heart failure ( New York Heart Association ( NYHA ) class III IV ) , recent cerebrovascular accident condition , opinion investigator , would put subject risk participation protocol . Evidence dysplasia history malignancy ( include lymphoma leukemia ) successfully treat nonmetastatic cutaneous squamous cell basal cell carcinoma localize carcinoma situ cervix . Subject receive live vaccine within 3 month prior study drug administration . Subject history clinically significant hematologic ( e.g. , severe anemia , leukopenia , thrombocytopenia ) , renal liver disease ( e.g. , fibrosis , cirrhosis , hepatitis ) . Positive pregnancy test Screening Baseline . Subject consider investigator , reason , unsuitable candidate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Pharmacodynamic , Pharmacokinetic</keyword>
</DOC>